NRXPHealthcare · BiotechnologyThe 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. hold a median 12-month price target of $47 — +1231.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores NRX Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (71): Smaller than most of the companies we track.
Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NRXP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1231.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | BTIG | Reiterates | Buy | $10 |
| 7 Aug 2026 | BTIG | Maintains | Buy | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | $25 → $10 |
| 5 May 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 May 2026 | D. Boral Capital | Maintains | Buy | $34 |
| 27 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 24 Mar 2026 | BTIG | Reiterates | Buy | — |
| 24 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 17 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 3 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Feb 2026 | BTIG | Reiterates | Buy | — |
| 17 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 15 Jan 2026 | BTIG | Reiterates | Buy | — |
| 5 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 2 Jan 2026 | Ascendiant Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRXP appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 5% of US stocks
Cheaper than 97% of US stocks
Cheaper than 80% of US stocks
Higher than 49% of US stocks
Higher than 52% of US stocks
Higher than 8% of US stocks
Higher than 97% of US stocks
Higher than 98% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NRX Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NRx Pharmaceuticals, Inc. (NRXP) held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and business update.
Why it matters — NRXP watchers would care because the earnings call transcript provides direct insight into the company's latest financial performance and management commentary.
NRx Pharmaceuticals reported its second quarter 2026 financial results and provided a corporate update. The company completed the first-cycle FDA review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, and the sole remaining item—a manufacturer's attestation on the vial—has been submitted to the FDA. A conference call is scheduled for Monday, August 17th at 4:30pm ET.
Why it matters — NRXP watchers would care because the ANDA review progress for preservative-free ketamine indicates the company is advancing toward potential FDA approval of a key product.
NRx Pharmaceuticals reported a Q2 loss of $0.18 per share, wider than the Zacks Consensus Estimate of a $0.09 loss, and missed revenue estimates. The loss improved from $0.98 per share a year earlier.
Why it matters — NRXP watchers would care because the company's second-quarter results came in below analyst expectations on both earnings and revenue, despite narrowing its year-over-year loss.
NRx Pharmaceuticals held a discussion covering the FDA's first cycle review outcome for its preservative-free ketamine product and its commercialization plans. The coverage appears on Seeking Alpha as a transcript of the company's remarks.
Why it matters — FDA review progress for its preservative-free ketamine and the associated commercialization strategy are central to NRXP's near-term outlook.
NRx Pharmaceuticals reported it has completed the first-cycle FDA review of its abbreviated new drug application for preservative-free ketamine, with one remaining issue related to the product's vial connector still to be resolved before a decision.
Why it matters — NRXP watchers would track this because the nearly complete FDA review could bring the company closer to potentially clearing the last hurdle for approval of its preservative-free ketamine product.
The 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. have a median 12-month price target of $47, with estimates ranging from $10 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering NRX Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NRX Pharmaceuticals, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, NRX Pharmaceuticals, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +1231.4% from the last close, and Ticker Nerd's factor model ranks NRX Pharmaceuticals, Inc. 20 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NRX Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $49 over the next 12 months.
NRX Pharmaceuticals, Inc. returned +39.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders with high unmet medical need.
The most recent item we track (Seeking Alpha, 18 Aug 2026): "NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript". NRx Pharmaceuticals, Inc. (NRXP) held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and business update.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders with high unmet medical need. The company concentrates on severe psychiatric and neurological conditions, particularly suicidal depression, suicidal bipolar depression, chronic pain, and post-traumatic stress disorder. Its pipeline is built around an NMDA-targeted platform, including NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being studied in Phase 2/3 settings. These products aim to address acute suicidality and related symptoms where existing therapies are limited or inadequate, and have received U.S. FDA designations such as Fast Track and Breakthrough Therapy for specific indications. NRx Pharmaceuticals also operates through related segments and initiatives in interventional psychiatry and healthcare delivery. Founded in 2017 and headquartered in Wilmington, Delaware, the company plays a specialized role in the biopharmaceutical market by targeting life-threatening mental health conditions and complex CNS disorders with differentiated, mechanism-based drug candidates.
CEO Dr. Jonathan C. Javitt M.D., M.P.H. · 29 employees · United States · https://www.nrxpharma.com